Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
"Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology.

Frontiers in psychology

Di Mattei VE, Carnelli L, Taranto P, Bernardi M, Brombin C, Cugnata F, Noviello A, Currin M, Mangili G, Rabaiotti E, Sarno L, Candiani M.
PMID: 28983271
Front Psychol. 2017 Sep 21;8:1633. doi: 10.3389/fpsyg.2017.01633. eCollection 2017.

No abstract available.

Cite
Di Mattei VE, Carnelli L, Taranto P, et al. "Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology. Front Psychol. 2017;8:1633doi: 10.3389/fpsyg.2017.01633.
Di Mattei, V. E., Carnelli, L., Taranto, P., Bernardi, M., Brombin, C., Cugnata, F., Noviello, A., Currin, M., Mangili, G., Rabaiotti, E., Sarno, L., & Candiani, M. (2017). "Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology. Frontiers in psychology, 81633. https://doi.org/10.3389/fpsyg.2017.01633
Di Mattei, Valentina E, et al. ""Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology." Frontiers in psychology vol. 8 (2017): 1633. doi: https://doi.org/10.3389/fpsyg.2017.01633
Di Mattei VE, Carnelli L, Taranto P, Bernardi M, Brombin C, Cugnata F, Noviello A, Currin M, Mangili G, Rabaiotti E, Sarno L, Candiani M. "Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology. Front Psychol. 2017 Sep 21;8:1633. doi: 10.3389/fpsyg.2017.01633. eCollection 2017. PMID: 28983271; PMCID: PMC5613306.
Copy Download .nbib Format: NLM
IMA Genome-F 2: Ceratocystis manginecans, Ceratocystis moniliformis, Diplodia sapinea: Draft genome sequences of Diplodia sapinea, Ceratocystis manginecans, and Ceratocystis moniliformis.

IMA fungus

van der Nest MA, Bihon W, De Vos L, Naidoo K, Roodt D, Rubagotti E, Slippers B, Steenkamp ET, Wilken PM, Wilson A, Wingfield MJ, Wingfield BD.
PMID: 25083413
IMA Fungus. 2014 Jun;5(1):135-40. doi: 10.5598/imafungus.2014.05.01.13. Epub 2014 Jun 19.

The draft nuclear genomes of Diplodia sapinea, Ceratocystis moniliformis s. str., and C. manginecans are presented. Diplodia sapinea is an important shoot-blight and canker pathogen of Pinus spp., C. moniliformis is a saprobe associated with wounds on a wide...

Cite
van der Nest MA, Bihon W, De Vos L, et al. IMA Genome-F 2: Ceratocystis manginecans, Ceratocystis moniliformis, Diplodia sapinea: Draft genome sequences of Diplodia sapinea, Ceratocystis manginecans, and Ceratocystis moniliformis. IMA Fungus. 2014;5(1):135-40doi: 10.5598/imafungus.2014.05.01.13.
van der Nest, M. A., Bihon, W., De Vos, L., Naidoo, K., Roodt, D., Rubagotti, E., Slippers, B., Steenkamp, E. T., Wilken, P. M., Wilson, A., Wingfield, M. J., & Wingfield, B. D. (2014). IMA Genome-F 2: Ceratocystis manginecans, Ceratocystis moniliformis, Diplodia sapinea: Draft genome sequences of Diplodia sapinea, Ceratocystis manginecans, and Ceratocystis moniliformis. IMA fungus, 5(1), 135-40. https://doi.org/10.5598/imafungus.2014.05.01.13
van der Nest, Magriet A, et al. "IMA Genome-F 2: Ceratocystis manginecans, Ceratocystis moniliformis, Diplodia sapinea: Draft genome sequences of Diplodia sapinea, Ceratocystis manginecans, and Ceratocystis moniliformis." IMA fungus vol. 5,1 (2014): 135-40. doi: https://doi.org/10.5598/imafungus.2014.05.01.13
van der Nest MA, Bihon W, De Vos L, Naidoo K, Roodt D, Rubagotti E, Slippers B, Steenkamp ET, Wilken PM, Wilson A, Wingfield MJ, Wingfield BD. IMA Genome-F 2: Ceratocystis manginecans, Ceratocystis moniliformis, Diplodia sapinea: Draft genome sequences of Diplodia sapinea, Ceratocystis manginecans, and Ceratocystis moniliformis. IMA Fungus. 2014 Jun;5(1):135-40. doi: 10.5598/imafungus.2014.05.01.13. Epub 2014 Jun 19. PMID: 25083413; PMCID: PMC4107891.
Copy Download .nbib Format: NLM
Erratum to 'What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome' [European Journal of Surgical Oncology 46/5 (2020) 888-892].

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Candotti G, Peiretti M, Mangili G, Bergamini A, Candiani M, Cioffi R, Mais V, Rabaiotti E, Bocciolone L.
PMID: 32739220
Eur J Surg Oncol. 2020 Oct;46(10):1972. doi: 10.1016/j.ejso.2020.07.021. Epub 2020 Jul 30.

No abstract available.

Cite
Candotti G, Peiretti M, Mangili G, et al. Erratum to 'What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome' [European Journal of Surgical Oncology 46/5 (2020) 888-892]. Eur J Surg Oncol. 2020;46(10):1972doi: 10.1016/j.ejso.2020.07.021.
Candotti, G., Peiretti, M., Mangili, G., Bergamini, A., Candiani, M., Cioffi, R., Mais, V., Rabaiotti, E., & Bocciolone, L. (2020). Erratum to 'What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome' [European Journal of Surgical Oncology 46/5 (2020) 888-892]. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 46(10), 1972. https://doi.org/10.1016/j.ejso.2020.07.021
Candotti, Giorgio, et al. "Erratum to 'What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome' [European Journal of Surgical Oncology 46/5 (2020) 888-892]." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology vol. 46,10 (2020): 1972. doi: https://doi.org/10.1016/j.ejso.2020.07.021
Candotti G, Peiretti M, Mangili G, Bergamini A, Candiani M, Cioffi R, Mais V, Rabaiotti E, Bocciolone L. Erratum to 'What women want: Fertility sparing surgery in Borderline ovarian tumours patients and pregnancy outcome' [European Journal of Surgical Oncology 46/5 (2020) 888-892]. Eur J Surg Oncol. 2020 Oct;46(10):1972. doi: 10.1016/j.ejso.2020.07.021. Epub 2020 Jul 30. PMID: 32739220.
Copy Download .nbib Format: NLM
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer.

Translational oncology

Cattrini C, Barboro P, Rubagotti A, Zinoli L, Zanardi E, Capaia M, Boccardo F.
PMID: 32416542
Transl Oncol. 2020 Jul;13(7):100789. doi: 10.1016/j.tranon.2020.100789. Epub 2020 May 14.

Periostin (POSTN) is an extracellular matrix protein associated with tumor progression and shorter survival in prostate cancer (PCa). Here, we performed an integrative analysis of POSTN's role in patients with PCa. Clinical and POSTN data from large-scale datasets were...

Cite
Cattrini C, Barboro P, Rubagotti A, et al. Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer. Transl Oncol. 2020;13(7):100789doi: 10.1016/j.tranon.2020.100789.
Cattrini, C., Barboro, P., Rubagotti, A., Zinoli, L., Zanardi, E., Capaia, M., & Boccardo, F. (2020). Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer. Translational oncology, 13(7), 100789. https://doi.org/10.1016/j.tranon.2020.100789
Cattrini, Carlo, et al. "Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer." Translational oncology vol. 13,7 (2020): 100789. doi: https://doi.org/10.1016/j.tranon.2020.100789
Cattrini C, Barboro P, Rubagotti A, Zinoli L, Zanardi E, Capaia M, Boccardo F. Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer. Transl Oncol. 2020 Jul;13(7):100789. doi: 10.1016/j.tranon.2020.100789. Epub 2020 May 14. PMID: 32416542; PMCID: PMC7248449.
Copy Download .nbib Format: NLM
Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling.

Frontiers in psychology

Di Mattei VE, Carnelli L, Bernardi M, Bienati R, Brombin C, Cugnata F, Rabaiotti E, Zambetti M, Sarno L, Candiani M, Gentilini O.
PMID: 30061853
Front Psychol. 2018 Jul 16;9:1218. doi: 10.3389/fpsyg.2018.01218. eCollection 2018.

No abstract available.

Cite
Di Mattei VE, Carnelli L, Bernardi M, et al. Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling. Front Psychol. 2018;9:1218doi: 10.3389/fpsyg.2018.01218.
Di Mattei, V. E., Carnelli, L., Bernardi, M., Bienati, R., Brombin, C., Cugnata, F., Rabaiotti, E., Zambetti, M., Sarno, L., Candiani, M., & Gentilini, O. (2018). Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling. Frontiers in psychology, 91218. https://doi.org/10.3389/fpsyg.2018.01218
Di Mattei, Valentina E, et al. "Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling." Frontiers in psychology vol. 9 (2018): 1218. doi: https://doi.org/10.3389/fpsyg.2018.01218
Di Mattei VE, Carnelli L, Bernardi M, Bienati R, Brombin C, Cugnata F, Rabaiotti E, Zambetti M, Sarno L, Candiani M, Gentilini O. Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling. Front Psychol. 2018 Jul 16;9:1218. doi: 10.3389/fpsyg.2018.01218. eCollection 2018. PMID: 30061853; PMCID: PMC6055025.
Copy Download .nbib Format: NLM
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Therapeutic advances in medical oncology

Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F.
PMID: 29383035
Ther Adv Med Oncol. 2018 Jan 09;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018.

BACKGROUND: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials,...

Cite
Cavo A, Rubagotti A, Zanardi E, et al. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018;10:1758834017745819doi: 10.1177/1758834017745819.
Cavo, A., Rubagotti, A., Zanardi, E., Fabbroni, C., Zinoli, L., Di Meglio, A., Arboscello, E., Bellodi, A., Spallarossa, P., Cattrini, C., Messina, C., & Boccardo, F. (2018). Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Therapeutic advances in medical oncology, 101758834017745819. https://doi.org/10.1177/1758834017745819
Cavo, Alessia, et al. "Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes." Therapeutic advances in medical oncology vol. 10 (2018): 1758834017745819. doi: https://doi.org/10.1177/1758834017745819
Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018 Jan 09;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018. PMID: 29383035; PMCID: PMC5784574.
Copy Download .nbib Format: NLM
[¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Mangili G, Bergamini A, Giorgione V, Picchio M, Petrone M, Mapelli P, Rabaiotti E, Incerti E, Candiani M.
PMID: 26868372
Q J Nucl Med Mol Imaging. 2016 Jun;60(2):103-16. Epub 2016 Feb 11.

INTRODUCTION: Gestational trophoblastic disease (GTD) is a group of different pregnancy-related diseases that includes hydatidiform mole (HM), invasive mole, gestational choriocarcinoma (CC), placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). The potential role of 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG) positron...

Cite
Mangili G, Bergamini A, Giorgione V, et al. [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective. Q J Nucl Med Mol Imaging. 2016;60(2):103-16
Mangili, G., Bergamini, A., Giorgione, V., Picchio, M., Petrone, M., Mapelli, P., Rabaiotti, E., Incerti, E., & Candiani, M. (2016). [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 60(2), 103-16.
Mangili, Giorgia, et al. "[¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective." The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... vol. 60,2 (2016): 103-16.
Mangili G, Bergamini A, Giorgione V, Picchio M, Petrone M, Mapelli P, Rabaiotti E, Incerti E, Candiani M. [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective. Q J Nucl Med Mol Imaging. 2016 Jun;60(2):103-16. Epub 2016 Feb 11. PMID: 26868372.
Copy Download .nbib Format: NLM
Tracking development assistance for health from China, 2007-2017.

BMJ global health

Micah AE, Zhao Y, Chen CS, Zlavog BS, Tsakalos G, Chapin A, Gloyd S, Jonas J, Lee PH, Liu S, Ng MTA, Phillips MR, Rubagotti E, Tang K, Tang S, Younis M, Zhang Y, Murray CJL, Dieleman JL.
PMID: 31646007
BMJ Glob Health. 2019 Oct 08;4(5):e001513. doi: 10.1136/bmjgh-2019-001513. eCollection 2019.

INTRODUCTION: In recent years, China has increased its international engagement in health. Nonetheless, the lack of data on contributions has limited efforts to examine contributions from China. Existing estimates that track development assistance for health (DAH) from China have...

Cite
Micah AE, Zhao Y, Chen CS, et al. Tracking development assistance for health from China, 2007-2017. BMJ Glob Health. 2019;4(5):e001513doi: 10.1136/bmjgh-2019-001513.
Micah, A. E., Zhao, Y., Chen, C. S., Zlavog, B. S., Tsakalos, G., Chapin, A., Gloyd, S., Jonas, J., Lee, P. H., Liu, S., Ng, M. T. A., Phillips, M. R., Rubagotti, E., Tang, K., Tang, S., Younis, M., Zhang, Y., Murray, C. J. L., & Dieleman, J. L. (2019). Tracking development assistance for health from China, 2007-2017. BMJ global health, 4(5), e001513. https://doi.org/10.1136/bmjgh-2019-001513
Micah, Angela E, et al. "Tracking development assistance for health from China, 2007-2017." BMJ global health vol. 4,5 (2019): e001513. doi: https://doi.org/10.1136/bmjgh-2019-001513
Micah AE, Zhao Y, Chen CS, Zlavog BS, Tsakalos G, Chapin A, Gloyd S, Jonas J, Lee PH, Liu S, Ng MTA, Phillips MR, Rubagotti E, Tang K, Tang S, Younis M, Zhang Y, Murray CJL, Dieleman JL. Tracking development assistance for health from China, 2007-2017. BMJ Glob Health. 2019 Oct 08;4(5):e001513. doi: 10.1136/bmjgh-2019-001513. eCollection 2019. PMID: 31646007; PMCID: PMC6782043.
Copy Download .nbib Format: NLM
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

Cancers

Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D.
PMID: 31547436
Cancers (Basel). 2019 Sep 12;11(9). doi: 10.3390/cancers11091355.

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several...

Cite
Cattrini C, Castro E, Lozano R, et al. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091355.
Cattrini, C., Castro, E., Lozano, R., Zanardi, E., Rubagotti, A., Boccardo, F., & Olmos, D. (2019). Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers, 11(9), . https://doi.org/10.3390/cancers11091355
Cattrini, Carlo, et al. "Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091355
Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2019 Sep 12;11(9). doi: 10.3390/cancers11091355. PMID: 31547436; PMCID: PMC6770296.
Copy Download .nbib Format: NLM
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.

Cancers

Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F.
PMID: 31540293
Cancers (Basel). 2019 Sep 13;11(9). doi: 10.3390/cancers11091365.

BACKGROUND: Circulating tumor cells (CTC), androgen receptor full-length (AR-FL), and androgen receptor splice variant 7 (AR-V7) are prognostic in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). AR-V7 seems to predict resistance to androgen-receptor signaling inhibitors (ARSi).METHODS: We assessed...

Cite
Cattrini C, Rubagotti A, Zinoli L, et al. Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091365.
Cattrini, C., Rubagotti, A., Zinoli, L., Cerbone, L., Zanardi, E., Capaia, M., Barboro, P., & Boccardo, F. (2019). Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. Cancers, 11(9), . https://doi.org/10.3390/cancers11091365
Cattrini, Carlo, et al. "Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091365
Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F. Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. Cancers (Basel). 2019 Sep 13;11(9). doi: 10.3390/cancers11091365. PMID: 31540293; PMCID: PMC6770005.
Copy Download .nbib Format: NLM
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer.

Cancers

Cattrini C, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, Messina C, Castro E, Olmos D, Boccardo F.
PMID: 33022939
Cancers (Basel). 2020 Oct 03;12(10). doi: 10.3390/cancers12102855.

The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance,...

Cite
Cattrini C, Soldato D, Rubagotti A, et al. Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers (Basel). 2020;12(10)doi: 10.3390/cancers12102855.
Cattrini, C., Soldato, D., Rubagotti, A., Zinoli, L., Zanardi, E., Barboro, P., Messina, C., Castro, E., Olmos, D., & Boccardo, F. (2020). Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers, 12(10), . https://doi.org/10.3390/cancers12102855
Cattrini, Carlo, et al. "Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer." Cancers vol. 12,10 (2020). doi: https://doi.org/10.3390/cancers12102855
Cattrini C, Soldato D, Rubagotti A, Zinoli L, Zanardi E, Barboro P, Messina C, Castro E, Olmos D, Boccardo F. Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers (Basel). 2020 Oct 03;12(10). doi: 10.3390/cancers12102855. PMID: 33022939; PMCID: PMC7650780.
Copy Download .nbib Format: NLM
A rare case of a giant arterio-venous fistula (AVF) following metastatic choriocarcinoma conditioning pulmonary embolism: multimodal transcatheter embolization using a simultaneous transarterial and transvenous approach.

CVIR endovascular

Venturini M, Bergamini A, Colarieti A, Petrone M, Marra P, Rabaiotti E, Mangili G, Candiani M, Del Maschio A, De Cobelli F.
PMID: 30652161
CVIR Endovasc. 2018;1(1):30. doi: 10.1186/s42155-018-0039-8. Epub 2018 Nov 20.

BACKGROUND: Choriocarcinoma is a highly malignant tumor but with a good prognosis due to the valid response to systemic chemotherapy. We present a case of a young woman affected by a giant pelvic arterio-venous fistula following a metastatic gestational...

Cite
Venturini M, Bergamini A, Colarieti A, et al. A rare case of a giant arterio-venous fistula (AVF) following metastatic choriocarcinoma conditioning pulmonary embolism: multimodal transcatheter embolization using a simultaneous transarterial and transvenous approach. CVIR Endovasc. 2018;1(1):30doi: 10.1186/s42155-018-0039-8.
Venturini, M., Bergamini, A., Colarieti, A., Petrone, M., Marra, P., Rabaiotti, E., Mangili, G., Candiani, M., Del Maschio, A., & De Cobelli, F. (2018). A rare case of a giant arterio-venous fistula (AVF) following metastatic choriocarcinoma conditioning pulmonary embolism: multimodal transcatheter embolization using a simultaneous transarterial and transvenous approach. CVIR endovascular, 1(1), 30. https://doi.org/10.1186/s42155-018-0039-8
Venturini, Massimo, et al. "A rare case of a giant arterio-venous fistula (AVF) following metastatic choriocarcinoma conditioning pulmonary embolism: multimodal transcatheter embolization using a simultaneous transarterial and transvenous approach." CVIR endovascular vol. 1,1 (2018): 30. doi: https://doi.org/10.1186/s42155-018-0039-8
Venturini M, Bergamini A, Colarieti A, Petrone M, Marra P, Rabaiotti E, Mangili G, Candiani M, Del Maschio A, De Cobelli F. A rare case of a giant arterio-venous fistula (AVF) following metastatic choriocarcinoma conditioning pulmonary embolism: multimodal transcatheter embolization using a simultaneous transarterial and transvenous approach. CVIR Endovasc. 2018;1(1):30. doi: 10.1186/s42155-018-0039-8. Epub 2018 Nov 20. PMID: 30652161; PMCID: PMC6319539.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries